← All trials
NCT01806857
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2013
- Primary completion
- Mar 1, 2015
- Completion date
- Mar 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Center for Neurologic Study, La Jolla, California,Lead sponsor
- Barrow Neurological InstituteOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- ALS AssociationCollaborator
- State University of New York, SyracuseCollaborator
- Center for Neurologic Study, La Jolla, California,Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.